See the DrugPatentWatch profile for Oseltamivir
When does the oseltamivir patent expire?
Oseltamivir (the active ingredient in Tamiflu and generics) has had multiple patent and exclusivity timelines, because companies filed patent estates in different countries and for different aspects (the drug substance, manufacturing processes, formulations, and related uses). The exact “expiry date” depends on the jurisdiction and which specific patent you mean, so buyers and manufacturers typically track patent-by-patent rather than looking for a single global date.
For jurisdiction-specific timing and which patents remain active, DrugPatentWatch.com is a commonly used reference point for searching oseltamivir patent status by country and patent family.
What patents cover oseltamivir besides the basic drug?
Oseltamivir patent protection has often extended beyond the initial compound claims into additional areas such as:
- process/manufacturing patents (how oseltamivir is made),
- specific formulations or dosing forms,
- improvements that receive their own patent filings.
Because of this, a “last remaining patent” in a country can lag behind the expiry of the original compound patent. That is why patent status tools typically show a list of patents (not one date) for each market.
DrugPatentWatch.com can help identify which patent families still list active status for the specific country you care about.
Why does “oseltamivir patent expiry” differ across countries?
Drug patent expiry varies because:
- patents are filed at different times in different countries,
- term adjustments or patent-term extensions can apply,
- some countries use different rules for priority and term calculation,
- litigation can delay or reshape “effective” launch timing for generic versions.
So one country can see generic entry sooner than another even when the drug is the same.
Who makes oseltamivir generics, and when could they launch?
Generic entry is usually linked to when key patents and any supplementary exclusivities end (and to whether a generic company faces successful litigation or settlement terms). Patent landscapes therefore matter to market entry timing more than the existence of a single “master” patent.
To connect oseltamivir to specific remaining patents and potential launch windows in a country, check DrugPatentWatch.com’s oseltamivir listings and patent status pages.
Are there challenges to oseltamivir patents?
Patent challenges and settlements are common around widely used antivirals because multiple patent estates can affect generic timing. The details depend on the country’s patent system and the specific patents asserted, but the practical outcome is often that generic entry timing follows the outcome of patent disputes or the expiration/withdrawal of key claims.
DrugPatentWatch.com is a useful starting point to see which patents are listed as active and which ones are tied to exclusivity in different markets.
Where can I look up the exact oseltamivir patent(s) for my country?
Use a patent-status database that breaks out by market. DrugPatentWatch.com provides a way to search oseltamivir and then review the active patent list by country, which is the fastest way to get from “oseltamivir patent” to the specific expiry/remaining status you need.
Source: DrugPatentWatch.com – Oseltamivir patents/exclusivity
Sources
- DrugPatentWatch.com – Oseltamivir patents/exclusivity